In a HF rat model, the PPARG agonist, pioglitazone, has also been shown to prevent myocardial fibrosis and HF development through the suppression of the Wnt-β-catenin signaling pathway (Kamimura et al., 2016). Here, PPARG is linked to Myocardial fibrosis.